{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:24:17Z","timestamp":1787117057023,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babe\u0219 University of Medicine and Pharmacy Timi\u0219oara"},{"id":[{"id":"https:\/\/ror.org\/00afdp487","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Native valvular heart disease (VHD) lacks established lesion-modifying pharmacotherapy. Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is) improve heart-failure and cardiorenal outcomes, but their relevance to VHD differs by phenotype and treatment setting. Methods: MEDLINE\/PubMed, Scopus, Web of Science Core Collection and Cochrane CENTRAL were searched from inception to 27 July 2026, together with trial registries, conference proceedings and reference lists. Evidence was synthesized by clinical setting, study design and mechanistic proximity to valve tissue. Results: Functional\/secondary mitral regurgitation (MR) currently provides the most convincing valve-related signal: EFFORT and DEFORM showed concordant reductions in MR severity with favorable remodeling surrogates, consistent with HF-directed unloading rather than a primary leaflet effect. DapaTAVI provides the strongest hard-outcome evidence after the mechanical correction of aortic stenosis, reducing the 1-year death\/worsening-HF composite in selected high-risk patients. In 28,940 HF patients from the SHEBAHEART registry, SGLT2i use was associated with reduced death\/HF hospitalization and a 28% lower adjusted risk of tricuspid-regurgitation progression, but these data remain observational. Native aortic-stenosis progression is supported only by target-trial emulation, and no dedicated clinical evidence exists for native aortic regurgitation. Conclusions: SGLT2is should be integrated into guideline-directed HF therapy when indicated. In secondary MR, reassessment after optimized therapy should precede mitral intervention when clinically appropriate. A post-TAVI benefit should be interpreted as cardiorenal\/HF protection, not valve modification. The current evidence does not justify SGLT2is solely to modify an untreated native valve lesion.<\/jats:p>","DOI":"10.3390\/jcm15166355","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:35:08Z","timestamp":1786984508000},"page":"6355","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibitors in Valvular Heart Disease: Cardiovascular Benefit, Valve-Specific Effects, and Evidence Gaps\u2014A Structured Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Maria","family":"Rada","sequence":"first","affiliation":[{"name":"Department VI\u2014Cardiology, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Laura","family":"Craciun","sequence":"additional","affiliation":[{"name":"Department VI\u2014Cardiology, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6025-5998","authenticated-orcid":false,"given":"Ana-Maria","family":"Pah","sequence":"additional","affiliation":[{"name":"Department VI\u2014Cardiology, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe Stoichescu","family":"Hogea","sequence":"additional","affiliation":[{"name":"Department VI\u2014Cardiology, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gurgus","sequence":"additional","affiliation":[{"name":"Department XVI\u2014Balneology, Medical Rehabilitation and Rheumatology, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5501-1290","authenticated-orcid":false,"given":"Milan Daniel","family":"Velimirovici","sequence":"additional","affiliation":[{"name":"Department I\u2014Nursing, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Alexandru","family":"Surducan","sequence":"additional","affiliation":[{"name":"Department III\u2014Functional Sciences, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdeldayem","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7708-7314","authenticated-orcid":false,"given":"Diana","family":"Utu","sequence":"additional","affiliation":[{"name":"Department II\u2014Physiology and Pathophysiology, Faculty of Pharmacy, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7868-9266","authenticated-orcid":false,"given":"Cristiana-Adina","family":"Avram","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Pedersen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/CIRCULATIONAHA.119.043391","article-title":"Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990\u20132017","volume":"141","author":"Yadgir","year":"2020","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199907153410302","article-title":"Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly","volume":"341","author":"Otto","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.jacc.2019.09.017","article-title":"Echocardiographic outcomes after transcatheter leaflet approximation in patients with secondary mitral regurgitation: The COAPT trial","volume":"74","author":"Asch","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/nrdp.2016.6","article-title":"Calcific aortic stenosis","volume":"2","author":"Lindman","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Liu, M., Li, F., Huang, Y., Zhou, T., Chen, S., Li, G., Shi, J., Dong, N., and Xu, K. (2020). Caffeic acid phenethyl ester ameliorates calcification by inhibiting activation of the AKT\/NF-\u03baB\/NLRP3 inflammasome pathway in human aortic valve interstitial cells. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00826"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1161\/ATVBAHA.112.300116","article-title":"Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2","volume":"32","author":"Song","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103183","DOI":"10.1016\/j.redox.2024.103183","article-title":"Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming","volume":"73","author":"Wu","year":"2024","journal-title":"Redox Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e70630","DOI":"10.1096\/fj.202403109R","article-title":"Canagliflozin delays aortic valve calcification by enhancing the AMPK\/Nrf2\/HO-1 antioxidant signaling pathway in valvular interstitial cells","volume":"39","author":"Zhao","year":"2025","journal-title":"FASEB J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.124.069144","article-title":"Ertugliflozin for functional mitral regurgitation associated with heart failure: EFFORT trial","volume":"149","author":"Kang","year":"2024","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/ehf2.15296","article-title":"Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial","volume":"12","author":"Huang","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jcin.2024.11.036","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on the progression of aortic stenosis","volume":"18","author":"Shah","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in patients undergoing transcatheter aortic-valve implantation","volume":"392","author":"Rossello","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_17","first-page":"B9","article-title":"TCT-185 clinical outcomes of SGLT2 inhibitors among patients undergoing mitral transcatheter edge-to-edge repair","volume":"84","author":"Thakkar","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ehaf784.2358","DOI":"10.1093\/eurheartj\/ehaf784.2358","article-title":"Effects on mitral and tricuspid valve regurgitation after 6 months of treatment with SGLT2 inhibitors in patients with chronic heart failure","volume":"46","author":"Basile","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Morel, O., Guglieri, M., Trimaille, A., Marchandot, B., Bisson, A., Granier, A., Schini-Kerth, V., Bernard, A., and Fauchier, L. (2026). Assessing potential valve-preserving effects of SGLT2 inhibitors in degenerative aortic stenosis: A propensity-matched study. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020714"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","article-title":"SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)","volume":"23","author":"Paolisso","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Morel, O., Granier, A., Lochon, L., Trimaille, A., Bisson, A., Marchandot, B., Bernard, A., and Fauchier, L. (2025). Association of SGLT2 inhibitors with mortality and bioprosthesis valve failure after TAVR: A propensity-matched cohort study. J. Clin. Med., 14.","DOI":"10.2139\/ssrn.5336439"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00228-026-04064-0","article-title":"Therapeutic impact of SGLT2 inhibitors following transcatheter aortic valve implantation: A GRADE-assessed systematic review and meta-analysis","volume":"82","author":"Hamzah","year":"2026","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101963","DOI":"10.1016\/j.ijcha.2026.101963","article-title":"SGLT2 inhibitors after transcatheter aortic valve implantation: A systematic review and exploratory meta-analysis","volume":"65","author":"Spadafora","year":"2026","journal-title":"IJC Heart Vasc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ehjcvp\/pvag018","article-title":"Heart failure and tricuspid regurgitation: The role of SGLT2 inhibitors in improving outcomes: Insights from SHEBAHEART big data registry","volume":"12","author":"Loutati","year":"2026","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtcvs.2013.05.011","article-title":"MicroRNA-30b is a multifunctional regulator of aortic valve interstitial cells","volume":"147","author":"Zhang","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e12666","DOI":"10.1111\/jpi.12666","article-title":"Melatonin ameliorates aortic valve calcification via the regulation of circular RNA CircRIC3\/miR-204-5p\/DPP4 signaling in valvular interstitial cells","volume":"69","author":"Wang","year":"2020","journal-title":"J. Pineal Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/ATVBAHA.116.308394","article-title":"Role of noncanonical Wnt signaling pathway in human aortic valve calcification","volume":"37","author":"Albanese","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41419-023-05642-1","article-title":"Rho A\/ROCK1 signaling-mediated metabolic reprogramming of valvular interstitial cells toward Warburg effect accelerates aortic valve calcification via AMPK\/RUNX2 axis","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1161\/ATVBAHA.120.314789","article-title":"Cell-type transcriptome atlas of human aortic valves reveal cell heterogeneity and endothelial to mesenchymal transition involved in calcific aortic valve disease","volume":"40","author":"Xu","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1161\/ATVBAHA.112.300226","article-title":"Endoplasmic reticulum stress participates in aortic valve calcification in hypercholesterolemic animals","volume":"33","author":"Cai","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/ATVBAHA.107.156745","article-title":"Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification","volume":"28","author":"Liberman","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101549","DOI":"10.1016\/j.molmet.2022.101549","article-title":"Cardiovascular protection by SGLT2 inhibitors\u2014Do anti-inflammatory mechanisms play a role?","volume":"64","author":"Elrakaybi","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: A substudy of the Empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_34","unstructured":"(2026, August 08). Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation (EVENT). ClinicalTrials.gov Identifier: NCT06027307, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06027307."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","article-title":"2025 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"46","author":"Praz","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Granata, L.G., Marchetta, M., Giubilato, S., Gulizia, M.M., Sangiorgi, G.M., and Francese, G.M. (2026). Transcatheter edge-to-edge repair for mitral regurgitation: Distinct interventional paradigms for primary and secondary MR. Hearts, 7.","DOI":"10.3390\/hearts7010008"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: A framework for causal inference from observational data","volume":"328","author":"Wang","year":"2022","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ehjcvp\/pvag021","article-title":"SGLT2 inhibitors in heart failure with tricuspid regurgitation: Clinical interpretation and future directions","volume":"12","author":"Dong","year":"2026","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jacasi.2026.03.034","article-title":"SGLT2 inhibition as a novel therapeutic strategy in rheumatic heart disease","volume":"6","author":"Morel","year":"2026","journal-title":"JACC Asia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ejhf.2370","article-title":"Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial","volume":"24","author":"Romaguera","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.3145","article-title":"Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study","volume":"26","author":"Scisciola","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107432","DOI":"10.1016\/j.ahj.2026.107432","article-title":"Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial","volume":"297","author":"Reinert","year":"2026","journal-title":"Am. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6355\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:29:45Z","timestamp":1787113785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":42,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166355"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166355","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}